SILVER SPRING
Alyftrek and Trikafta label expansions approved for cystic fibrosis
- Sponsor
- Vertex Pharmaceuticals Incorporated $VRTX
- Drug
- Alyftrek, Trikafta · vanzacaftor/tezacaftor/deutivacaftor, elexacaftor/tezacaftor/ivacaftor
- Indication
- cystic fibrosis
FDA approved expanded use of Alyftrek and Trikafta for cystic fibrosis treatment, increasing availability to ~95% of patients.
What this means
Trikafta and Alyftrek are combination drugs that help fix faulty chloride channels in people with cystic fibrosis, improving lung function. The FDA just expanded their approved uses to cover nearly all CF patients, including those with rare mutations. This means more people with the disease could access these treatments that target the root cause rather than just symptoms.